Silymarin ameliorates diabetic cardiomyopathy via inhibiting TGF‐β1/Smad signaling
Citations Over TimeTop 12% of 2018 papers
Abstract
Diabetic cardiomyopathy (DCM) is the leading cause of morbidity and mortality in diabetes mellitus (DM) patients. Previous studies have shown that the transforming growth factor-beta 1 (TGF-β1)/Smad signaling pathway plays a key role in the development of myocardial fibrosis in DCM. Silymarin (SMN) is used clinically to treat liver disorders and acts by influencing TGF-β1. However, the possible effects of silymarin on DCM remain to be elucidated. In our study, the DM animal model was induced by streptozotocin (STZ) injection. Fasting blood glucose level was measured, and the structure and function of the heart were measured by hematoxylin and eosin (H&E) and Masson staining, echocardiography, and transmission electron microscopy (TEM). Western blot was used to detect the expression of TGF-β1, Smad2/3, phosphorylation Smad2/3(p-Smad2/3), and Smad7. Our results showed that silymarin downregulated blood glucose level and significantly improved cardiac fibrosis and collagen deposition in DM rats detected by H&E, Masson staining, and TEM assays. The echocardiography results showed that silymarin administration attenuated cardiac dysfunction in DM rats. Additionally, compared with untreated DM rats, levels of TGF-β1 and p-Smad2/3 were decreased, whereas Smad7 was increased following silymarin administration. These data demonstrate that silymarin ameliorates DCM through the inhibition of TGF-β1/Smad signaling, suggesting that silymarin may be a potential target for DCM treatment.
Related Papers
- → FK506 inhibits the enhancing effects of transforming growth factor (TGF)-β1 on collagen expression and TGF-β/Smad signalling in keloid fibroblasts: implication for new therapeutic approach(2012)62 cited
- → FK506 inhibits the mice glomerular mesangial cells proliferation by affecting the transforming growth factor-βand Smads signal pathways(2014)15 cited
- → Expression of transforming‐growth‐factor (TGF)‐β receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGF‐β1(1999)1 cited
- → Relationship between Smad and transforming growth factor-β signal transduction pathway(2010)
- → Role of transforming growth factor-β/Smad pathway and related factors in the pathogenesis of keloids(2023)